HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 1 (2004), Issue 5 (December)

1. Seroprevalence of and risk factors for HIV-1 infection among South American men who have sex with men.
   Sex Transm Infect, 80(6): 498-504. [Abstract] [Full-text]
2. Proteins that bind high-mannose sugars of the HIV envelope.
   Prog Biophys Mol Biol, 88(2): 233-82. [Abstract] [Full-text]
3. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
   Prog Biophys Mol Biol, 88(2): 209-31. [Abstract] [Full-text]
4. Adaptive inhibitors of the HIV-1 protease.
   Prog Biophys Mol Biol, 88(2): 193-208. [Abstract] [Full-text]
5. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.
   J Clin Virol, 32(1): 60-6. [Abstract] [Full-text]
6. Assessment of sexually transmitted diseases as risk factors for HIV seroconversion in a New Orleans sexually transmitted disease clinic, 1990-1998.
   Ann Epidemiol, 15(1): 13-20. [Abstract] [Full-text]
7. Indigenous representations of illness and AIDS in Sub-Saharan Africa.
   Soc Sci Med, 60(4): 691-700. [Abstract] [Full-text]
8. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
   Eur J Immunol, 34(12): 3723-31. [Abstract] [Full-text]
9. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes.
   Eur J Immunol, 34(12): 3379-88. [Abstract] [Full-text]
10. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
    Genes Dev, 18(23): 2867-72. [Abstract] [Full-text]
11. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Genes Dev, 18(23): 2861-6. [Abstract] [Full-text]
12. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Biol Chem, 385(11): 1035-9. [Abstract] [Full-text]
13. Inhibited interpersonal coping style predicts poorer adherence to scheduled clinic visits in human immunodeficiency virus infected women at risk for cervical cancer.
    Ann Behav Med, 28(3): 195-202. [Abstract] [Full-text]
14. Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells.
    FASEB J, 18(15): 1961-3. [Abstract] [Full-text]
15. Neuroimaging correlates of HIV-associated BBB compromise.
    J Neuroimmunol, 157(1): 140-6. [Abstract] [Full-text]
16. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
    J Neuroimmunol, 157(1): 133-9. [Abstract] [Full-text]
17. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load.
    J Neuroimmunol, 157(1): 93-8. [Abstract] [Full-text]
18. Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: implications for HAD.
    J Neuroimmunol, 157(1): 17-26. [Abstract] [Full-text]
19. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease.
    J Neuroimmunol, 157(1): 11-6. [Abstract] [Full-text]
20. HIV dementia: an evolving disease.
    J Neuroimmunol, 157(1): 3-10. [Abstract] [Full-text]
21. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I.
    Clin Endocrinol (Oxf), 61(6): 692-9. [Abstract] [Full-text]
22. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
    Nat Med, 10(12): 1359-65. [Abstract] [Full-text]
23. Identification of talin head domain as an immunodominant epitope of the antiplatelet antibody response in patients with HIV-1-associated thrombocytopenia.
    Blood, 104(13): 4054-62. [Abstract] [Full-text]
24. Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR.
    J Clin Microbiol, 42(12): 5866-70. [Abstract] [Full-text]
25. Expression and characterization of Gag protein of HIV-1(CN) in Pichia pastoris.
    J Virol Methods, 123(1): 35-40. [Abstract] [Full-text]
26. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.
    J Virol Methods, 123(1): 25-34. [Abstract] [Full-text]
27. HIV-1 incorporates and proteolytically processes human NDR1 and NDR2 serine-threonine kinases.
    Virology, 331(1): 181-9. [Abstract] [Full-text]
28. Amphotericin-B-mediated reactivation of latent HIV-1 infection.
    Virology, 331(1): 106-16. [Abstract] [Full-text]
29. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Virology, 331(1): 82-93. [Abstract] [Full-text]
30. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Virology, 331(1): 33-46. [Abstract] [Full-text]
31. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
    Virology, 331(1): 20-32. [Abstract] [Full-text]
32. Apoptosis-related proteins and cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women.
    Gynecol Oncol, 95(3): 500-5. [Abstract] [Full-text]
33. APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles.
    J Mol Biol, 345(3): 547-58. [Abstract] [Full-text]
34. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail.
    J Cell Biol, 167(5): 903-13. [Abstract] [Full-text]
35. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA.
    Nat Biotechnol, 22(12): 1573-8. [Abstract] [Full-text]
36. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial.
    Int J Cancer, 113(4): 632-9. [Abstract] [Full-text]
37. Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients.
    J Gastrointest Surg, 8(8): 1024-30; discussion 1031. [Abstract] [Full-text]
38. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population.
    Immunol Lett, 96(2): 277-81. [Abstract] [Full-text]
39. Immunological analysis in paediatric HIV patients at different stages of the disease.
    Scand J Immunol, 60(6): 615-24. [Abstract] [Full-text]
40. Structural investigation of the HIV-1 envelope glycoprotein gp160 cleavage site 3: role of site-specific mutations.
    Chembiochem, 5(12): 1653-61. [Abstract] [Full-text]
41. Reducing plasma HIV RNA improves muscle amino acid metabolism.
    Am J Physiol Endocrinol Metab, 288(1): E278-84. [Abstract] [Full-text]
42. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis.
    J Infect Dis, 191(1): 25-32. [Abstract] [Full-text]
43. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease.
    J Infect Dis, 191(1): 4-10. [Abstract] [Full-text]
44. Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication.
    FEBS Lett, 578(3): 285-90. [Abstract] [Full-text]
45. Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue.
    Exp Neurol, 191(1): 2-12. [Abstract] [Full-text]
46. Electrostatic repulsion, compensatory mutations, and long-range non-additive effects at the dimerization interface of the HIV capsid protein.
    J Mol Biol, 345(4): 893-906. [Abstract] [Full-text]
47. Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus.
    J Ethnopharmacol, 96(1): 113-9. [Abstract] [Full-text]
48. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    AIDS Res Hum Retroviruses, 20(11): 1259-68. [Abstract] [Full-text]
49. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    AIDS Res Hum Retroviruses, 20(11): 1254-8. [Abstract] [Full-text]
50. Restricted entry of R5 HIV Type 1 strains into eosinophilic cells.
    AIDS Res Hum Retroviruses, 20(11): 1244-53. [Abstract] [Full-text]
51. The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death.
    AIDS Res Hum Retroviruses, 20(11): 1230-43. [Abstract] [Full-text]
52. Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages.
    AIDS Res Hum Retroviruses, 20(11): 1210-22. [Abstract] [Full-text]
53. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.
    AIDS Res Hum Retroviruses, 20(11): 1196-209. [Abstract] [Full-text]
54. Neonatal natural killer cells produce chemokines and suppress HIV replication in vitro.
    AIDS Res Hum Retroviruses, 20(11): 1189-95. [Abstract] [Full-text]
55. Altered replicative capacity of recombinant HIV type 1 containing mutations at codons 26 and 29 of the viral protease.
    AIDS Res Hum Retroviruses, 20(11): 1183-8. [Abstract] [Full-text]
56. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.
    AIDS Res Hum Retroviruses, 20(11): 1166-72. [Abstract] [Full-text]
57. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.
    AIDS Res Hum Retroviruses, 20(11): 1157-65. [Abstract] [Full-text]
58. Two viral strains and a possible novel recombinant are responsible for the explosive injecting drug use-associated HIV type 1 epidemic in Estonia.
    AIDS Res Hum Retroviruses, 20(11): 1148-56. [Abstract] [Full-text]
59. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS.
    BMC Psychiatry, 4: 38. [Abstract] [Full-text]
60. T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region.
    J Biol Chem, 279(51): 52949-60. [Abstract] [Full-text]
61. Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2.
    J Virol, 79(1): 632-6. [Abstract] [Full-text]
62. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    J Virol, 79(1): 626-31. [Abstract] [Full-text]
63. Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells.
    J Virol, 79(1): 602-8. [Abstract] [Full-text]
64. R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression.
    J Virol, 79(1): 458-71. [Abstract] [Full-text]
65. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination.
    J Virol, 79(1): 353-63. [Abstract] [Full-text]
66. Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.
    J Virol, 79(1): 264-76. [Abstract] [Full-text]
67. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.
    J Virol, 79(1): 176-83. [Abstract] [Full-text]
68. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression.
    J Virol, 79(1): 124-31. [Abstract] [Full-text]
69. The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.
    J Virol, 79(1): 106-15. [Abstract] [Full-text]
70. Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck.
    Biochemistry, 43(50): 15775-84. [Abstract] [Full-text]
71. One-year follow-up of orthopaedic implants in HIV-positive patients.
    Int Orthop, 28(6): 329-32. [Abstract] [Full-text]
72. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status.
    Gynecol Oncol, 96(1): 112-8. [Abstract] [Full-text]
73. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.
    Nature, 432(7018): 769-75. [Abstract] [Full-text]
74. Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion.
    J Gen Virol, 86: 131-8. [Abstract] [Full-text]
75. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.
    J Gen Virol, 86: 125-9. [Abstract] [Full-text]
76. A single-platform approach using flow cytometry and microbeads to evaluate immune reconstitution in mice after bone marrow transplantation.
    J Immunol Methods, 294(1): 53-66. [Abstract] [Full-text]
77. Docking dinucleotides to HIV-1 integrase carboxyl-terminal domain to find possible DNA binding sites.
    Bioorg Med Chem Lett, 15(2): 475-7. [Abstract] [Full-text]
78. Transmission of macrophage-tropic HIV-1 by breast-milk macrophages via DC-SIGN.
    J Infect Dis, 191(2): 174-81. [Abstract] [Full-text]
79. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort.
    J Infect Dis, 191(2): 159-63. [Abstract] [Full-text]
80. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners.
    J Infect Dis, 191(2): 150-8. [Abstract] [Full-text]
81. HIV-1 and the hijacking of dendritic cells: a tug of war.
    Springer Semin Immunopathol, 26(3): 309-28. [Abstract] [Full-text]
82. Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.
    Mol Immunol, 42(4): 557-60. [Abstract] [Full-text]
83. The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook.
    Health Policy, 71(2): 255-64. [Abstract] [Full-text]
84. Qualitative multiplex RT-PCR for simultaneous detection of hepatitis C virus and human immunodeficiency virus in plasma samples.
    Clin Microbiol Infect, 10(12): 1075-80. [Abstract] [Full-text]
85. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Br J Clin Pharmacol, 59(1): 38-42. [Abstract] [Full-text]
86. AIDS-related stigma and social interaction: Puerto Ricans living with HIV/AIDS.
    Qual Health Res, 15(2): 169-87. [Abstract] [Full-text]
87. Sexuality and sexual risk behavior in HIV-positive men who have sex with men.
    Qual Health Res, 15(2): 145-68. [Abstract] [Full-text]
88. Monoubiquitinated histone H1B is required for antiviral protection in CD4(+)T cells resistant to HIV-1.
    Biochemistry, 43(51): 16203-11. [Abstract] [Full-text]
89. Retention of conformational flexibility in HIV-1 Rev-RNA complexes.
    Biochemistry, 43(51): 16153-60. [Abstract] [Full-text]
90. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
    J Med Virol, 75(2): 202-8. [Abstract] [Full-text]
91. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
    J Med Virol, 75(2): 195-201. [Abstract] [Full-text]
92. HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor.
    J Exp Med, 200(12): 1547-57. [Abstract] [Full-text]
93. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Clin Infect Dis, 40(1): 158-63. [Abstract] [Full-text]
94. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    J Virol, 79(2): 1252-61. [Abstract] [Full-text]
95. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    J Virol, 79(2): 1154-63. [Abstract] [Full-text]
96. Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins.
    J Virol, 79(2): 1133-41. [Abstract] [Full-text]
97. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.
    J Virol, 79(2): 918-26. [Abstract] [Full-text]
98. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.
    J Virol, 79(2): 910-7. [Abstract] [Full-text]
99. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells.
    J Virol, 79(2): 869-75. [Abstract] [Full-text]
100. Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains.
     J Virol, 79(2): 860-8. [Abstract] [Full-text]
101. Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.
     J Virol, 79(2): 834-40. [Abstract] [Full-text]
102. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
     J Virol, 79(2): 823-33. [Abstract] [Full-text]
103. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
     J Virol, 79(2): 812-22. [Abstract] [Full-text]
104. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
     J Virol, 79(2): 780-90. [Abstract] [Full-text]
105. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
     J Virol, 79(2): 771-9. [Abstract] [Full-text]
106. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
     J Virol, 79(2): 764-70. [Abstract] [Full-text]
107. Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins.
     J Virol, 79(2): 756-63. [Abstract] [Full-text]
108. HIV-AIDS patients' evaluation of health information on the internet: the digital divide and vulnerability to fraudulent claims.
     J Consult Clin Psychol, 72(6): 1004-11. [Abstract] [Full-text]
109. Bone mineral and soft-tissue changes in AIDS-associated lipoatrophy.
     J Bone Miner Metab, 23(1): 53-7. [Abstract] [Full-text]
110. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
     Antimicrob Agents Chemother, 49(1): 342-9. [Abstract] [Full-text]
111. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.
     Antimicrob Agents Chemother, 49(1): 323-35. [Abstract] [Full-text]
112. Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.
     Antimicrob Agents Chemother, 49(1): 40-4. [Abstract] [Full-text]
113. Peptide immunogens designed to enhance immune responses against human immunodeficiency virus (HIV) mutant strains: a plausible means of preventing viral persistence.
     J Theor Biol, 233(1): 85-90. [Abstract] [Full-text]
114. Protective correlates against HIVs may have evolved in human populations in the areas of historic occurrence of primate-to-man transmissions of SIVs ancestral to HIVs: studies in these populations may provide crucial insights for treatment and prevention of HIV infection.
     Med Hypotheses, 64(3): 433-7. [Abstract] [Full-text]
115. Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients.
     Leuk Lymphoma, 46(1): 77-81. [Abstract] [Full-text]
116. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro.
     FEBS Lett, 579(1): 162-6. [Abstract] [Full-text]
117. Unprotected anal intercourse among HIV-positive men who have a steady male sex partner with negative or unknown HIV serostatus.
     Am J Public Health, 95(1): 152-8. [Abstract] [Full-text]
118. Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti.
     Am J Public Health, 95(1): 53-9. [Abstract] [Full-text]
119. Expanding access to antiretroviral therapy in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities.
     Am J Public Health, 95(1): 18-22. [Abstract] [Full-text]
120. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.
     Stat Med, 24(1): 65-82. [Abstract] [Full-text]
121. Potential public health impact of imperfect HIV type 1 vaccines.
     J Infect Dis, 191: S85-96. [Abstract] [Full-text]
122. Poly(ADP-ribose) polymerase-1 is a negative regulator of HIV-1 transcription through competitive binding to TAR RNA with Tat.positive transcription elongation factor b (p-TEFb) complex.
     J Biol Chem, 280(1): 448-57. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.